Introduction
============

Pancreatic cancer is the fourth-leading cause of cancer deaths in the US and has a very poor prognosis with a mortality approaching 100% ([@b1-ol-0-0-10113]--[@b4-ol-0-0-10113]). Only 15--20% of pancreatic cancer cases are diagnosed early due to nonspecific symptoms and approximately 50% of patients have metastasis at diagnosis ([@b5-ol-0-0-10113],[@b6-ol-0-0-10113]). As precision and personalized medicine emerged, research on the genomics of patients with various cancers to identify novel biomarkers is actively being pursued ([@b7-ol-0-0-10113],[@b8-ol-0-0-10113]).

γ-Secretase is an intramembrane-cleaving protease composed of an essential protein complex including γ-secretase complex-presenilin (PSEN), nicastrin (NCSTN), presenilin enhancer protein 2 (PSENEN), and anterior pharynx-defective 1 (APH1-) ([@b9-ol-0-0-10113],[@b10-ol-0-0-10113]). Either PSEN1 or PSEN2 contains NCSTN, the catalytic site, and the PSENEN and APH1 (APH1A or APH1B) substrate binding site ([@b10-ol-0-0-10113],[@b11-ol-0-0-10113]). Notch signaling is one of the most evolutionarily conserved pathways involved in cell fate control during development and postnatal tissue differentiation ([@b10-ol-0-0-10113],[@b12-ol-0-0-10113]). Aberrations in this signaling pathway have been identified in several diseases, including Alzheimer\'s disease, and malignancies ([@b10-ol-0-0-10113],[@b12-ol-0-0-10113]--[@b15-ol-0-0-10113]). γ-Secretase is not only able to cleave type I transmembrane proteins, but also the amyloid precursor protein and NOTCH receptors ([@b12-ol-0-0-10113]). Because abnormal activation of the Notch pathway plays a role in tumorigenesis, γ-secretase, which mediates Notch signals, is a promising therapeutic target ([@b12-ol-0-0-10113],[@b16-ol-0-0-10113]).

Several Notch signal inhibitors have been developed, including γ-secretase inhibitors (GSIs), siRNA, and monoclonal antibodies ([@b17-ol-0-0-10113],[@b18-ol-0-0-10113]). In *in vitro* studies, the administration of the GSI MRK-003 with gemcitabine decreased pancreatic adenocarcinoma cancer cell growth and suppressed cancer stem cells ([@b18-ol-0-0-10113]--[@b20-ol-0-0-10113]). In this context, γ-secretase is thought to play a significant role in tumorigenesis and survival in pancreatic cancer.

The present study retrospectively examined the prognostic significance of γ-secretase genes in patients with pancreatic cancer in independent cohorts. Among these genes, high expression of *APH1A* was significantly associated with a worse prognosis in patients with pancreatic cancer.

Materials and methods
=====================

### Patients

The patients\' data were downloaded from The Cancer Genome Atlas (TCGA) ([@b21-ol-0-0-10113],[@b22-ol-0-0-10113]) and the Gene Expression Omnibus (GEO, GSE21501, GSE28735, GSE15471, GSE16515) in October 2017 ([@b23-ol-0-0-10113]--[@b26-ol-0-0-10113]). We included only cohorts (TCGA, GSE21501) containing more than 100 patients with pancreatic cancer in which survival information was available. In TCGA and GSE21501, the cancer staging system follows The American Joint Committee on Cancer (AJCC) ([@b27-ol-0-0-10113]). These processes were performed using R software version 3.5.0 (The R Foundation for Statistical Computing, 2018), using the '*cgdsr*' and *'GEOquery'* packages.

### Survival and statistical analysis

Survival analyses were performed to predict the overall survival (OS). We used following three methods: i) Kaplan-Meier survival curves with log-rank test to evaluate the accuracy of the discrimination, ii) Uno\'s C-index in the time-dependent area under the curve (AUC) analysis, and iii) AUC values in receiver operating characteristics (ROC) at three years as we used previously ([@b28-ol-0-0-10113]--[@b31-ol-0-0-10113]). These values were calculated using the R packages '*survival*' and '*survAUC*'. C-indices and AUC values of 0.6 or greater were considered acceptable for survival predictions. In the Kaplan-Meier analyses, we determined the optimal cutoff value with the maximal Uno\'s C-index by five-fold cross-validation as we performed before ([@b30-ol-0-0-10113],[@b32-ol-0-0-10113]). We used univariate Cox regression to identify the effect of the genes on prognosis. To compare the γ-secretases expression value between tumor and non-tumor tissues, we used Wilcoxon signed rank test or t test according to their expression distribution in GSE28735, GSE15471 and GSE16515. All statistical analyses were performed using R.

Results
=======

### Patient distribution

In total, 172 patients (TCGA) and 102 patients (GSE21501) were included in this study. Their information is described in [Table I](#tI-ol-0-0-10113){ref-type="table"} and the characteristics of each cohort were quite different. The patients in TCGA were almost all at low stages (AJCC staging system, Stage I, 21; Stage II, 145; Stage III 3; Stage IV, 5), while the patients in GSE21501 were almost all at high stages (T1, 2; T2, 16; T3, 79; T4, 1; N0, 28; N1, 73). A flowchart of the present study is described in [Fig. 1](#f1-ol-0-0-10113){ref-type="fig"}. There are 45, 36 pairs of pancreatic tumor and adjacent non-tumor tissues in GSE28735, GSE15471. GSE16515 dataset consists of 36 tumors and 16 normal samples.

### Survival curve of γ-secretases

To identify the discriminatory power of γ-secretase genes as a categorical variable, we analyzed Kaplan-Meier curves with log-rank test for gene expression and survival. Among the γ-secretase genes, only *APH1A* was significantly associated with survival in both cohorts ([Figs. 2B](#f2-ol-0-0-10113){ref-type="fig"} and [3B](#f3-ol-0-0-10113){ref-type="fig"}). High expression of *PSEN1* and *PSENEN* showed a poor prognosis as the expression levels increased in both cohorts and were statistically significant in GSE21501 and TCGA respectively ([Figs. 2A and C](#f2-ol-0-0-10113){ref-type="fig"}, and [3A and C](#f3-ol-0-0-10113){ref-type="fig"}). The other genes were not statistically significant or showed opposite trends in each cohort ([Figs. 2](#f2-ol-0-0-10113){ref-type="fig"} and [3](#f3-ol-0-0-10113){ref-type="fig"}). The number of patients and deaths in the high- and low-risk groups divided by each gene are listed in [Table II](#tII-ol-0-0-10113){ref-type="table"}. The prognostic values were further confirmed using univariate Cox regression analysis ([Table III](#tIII-ol-0-0-10113){ref-type="table"}).

### C-index and AUC values of γ-secretase genes

We compared γ-secretase genes in both cohorts to evaluate their prognostic value. We analyzed the gene expression values as continuous variables using Uno\'s C-indices and AUC values at three years. *APH1A* had high C-index values in the two independent cohorts compared to those of the other genes ([Fig. 4](#f4-ol-0-0-10113){ref-type="fig"}). The three-year AUC value was also significantly higher than that of the other factors across the two cohorts ([Fig. 4](#f4-ol-0-0-10113){ref-type="fig"}).

### The differences of expression values between normal and tumor tissues

By using Wilcoxon rank sum test, we compared the expression of γ-secretase genes in three independent cohorts. As shown in [Table IV](#tIV-ol-0-0-10113){ref-type="table"}, the expression patterns of the γ-secretase genes except *APH1B* and *NCSTN* were statistically significant in agreement with the three independent cohorts. *APH1A*, the only statistically significant gene in survival curves, was found to be more expressed in cancer tissues compared to normal tissues in the three cohorts ([Fig. 5](#f5-ol-0-0-10113){ref-type="fig"} and [Table IV](#tIV-ol-0-0-10113){ref-type="table"}).

Discussion
==========

The present study investigated the prognostic significance of γ-secretase genes in pancreatic cancer using two independent cohorts each containing more than 100 patients. Although the characteristics of the two cohorts were quite different, high expression levels of *PSEN1, APH1A*, and *PSENEN* were associated with a poor prognosis in both cohorts. Especially, *APH1A* is the only statistically significant gene in all analyses.

Owing to the poor survival rate of pancreatic cancer, it is necessary to identify prognostic markers for patients to determine the precise treatment strategy. Although certain studies have attempted to predict the survival of patients with pancreatic cancer based on clinical variables and/or expression profiles, carbohydrate antigen 19-9 (CA-19-9) is the only biomarker approved by the US Food and Drug Administration (FDA) ([@b33-ol-0-0-10113],[@b34-ol-0-0-10113]). As the development of genetics and the importance of data sharing have been emphasized, relatively rare pancreatic cancer data have been collected and released. For the implementation of precision medicine, a number of cohorts and biomarkers verified in data from many patients are needed. Hence, we included and analyzed cohorts with more than 100 patients ([@b21-ol-0-0-10113]--[@b23-ol-0-0-10113]).

Notch signaling promotes the tumorigenesis of lung cancer in the hypoxic state ([@b12-ol-0-0-10113],[@b35-ol-0-0-10113]). In breast cancer, this signaling has been implicated in tumorigenesis ([@b36-ol-0-0-10113]--[@b38-ol-0-0-10113]). In this context, GSIs have been tested for their therapeutic activity in cancer cell lines (breast and lung) and several clinical trials ([@b12-ol-0-0-10113],[@b37-ol-0-0-10113],[@b39-ol-0-0-10113]). Moreover, the activation of Notch signals has been implicated in the progression of pancreatic cancer and MRK-003, a potent pan-NOTCH inhibitor has been shown to be an effective treatment for pancreatic adenocarcinoma ([@b19-ol-0-0-10113]). In our study, as the expression of some Notch substrates (*PSEN1, APH1A*, and *PSENEN*) increases, the prognosis of the patient worsens. Also, their expression levels of cancer are significantly higher than normal tissues. Thus, higher expression of them may play a significant role in tumor progression in pancreatic cancer. Our findings suggest that MRK-003 is in line with findings that is effective in the suppression of pancreatic cancer.

Some studies have reported that the different composition of six γ-secretase subunits have various enzymatic functions and cause varying physiological outcome. For instance, some researchers suggested that complexes in which the *PSEN1* and/or *APH1A* subunits were the major constituents could cause Alzheimer\'s disease if *PSEN2* and/or *APH1B* were changed to a major member ([@b40-ol-0-0-10113],[@b41-ol-0-0-10113]). In the current study, *APH1A, PSEN1*, and *PSENEN* increased in cancer tissues compared to normal tissues, while *PSEN2* decreased and *APH1B* and *NCSTN* did not change. These results suggested that they may play a role in the progression of pancreatic cancer. Especially, *APH1A* is closely related to survival, so *APH1A* is considered to play the most important role in changed γ-secretase subunits. Therefore, in future studies of pancreatic cancer, it will be necessary to study the role and function of *APH1A* as a major component of γ-secretase.

In conclusion, we found that the survival rate of patients with pancreatic cancer with high *PSEN1, APH1A*, and *PSENEN* expression was low. Although further studies are needed to assess the role of γ-secretase in tumorigenesis, our findings suggest that some γ-secretase substrates, especially *APH1A*, may have a critical role on the development and progression of pancreatic cancer. We believe that these findings will contribute to the prognostic prediction of pancreatic cancer.
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![Kaplan-Meier estimates of the overall survival of pancreatic cancer patients according to γ-secretase gene expression in the TCGA cohort. (A) *PSEN1*, (B) *APH1A*, (C) *PSENEN*, (D) *NSCTN*, (E) *PSEN2* and (F) *APH1B*. TCGA, The Cancer Genome Atlas; PSEN, presenilin; APH1, anterior pharynx-defective 1; PSENEN, presenilin enhancer protein 2; NCSTN, nicastrin.](ol-17-05-4614-g01){#f2-ol-0-0-10113}
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###### 

Patients\' information used in current research in the TCGA and GSE21501 cohorts.

  Group       Description                                                        TCGA    GSE21501
  ----------- ------------------------------------------------------------------ ------- ----------
  Male        --                                                                   94      −
  Female      --                                                                   78      −
  Stage I     --                                                                   21      −
  Stage II    --                                                                 145       −
  Stage III   --                                                                     3     −
  Stage IV    --                                                                     5     −
  T1          Confined to the pancreas, ≤2 cm in diameter                          −       2
  T2          Confined to the pancreas, 2 cm \< diameter ≤4 cm                     −     16
  T3          Confined to the pancreas, \>4 cm in diameter                         −     79
  T4          Extends outside the pancreas and into nearby major blood vessels     −       1
  N0          No spread to nearby lymph nodes                                      −     28
  N1          Spreads to no more than 3 nearby lymph nodes                         −     73

###### 

Number of patients (event) divided by each gene cutoff value.

  Gene               Group                     TCGA       GSE21501
  ------------------ ------------------------- ---------- ----------
  Total values (n)   All patients              172        102
  *PSEN1*            High expression (event)   107 (68)   61 (42)
                     Low expression (event)    65 (24)    41 (24)
  *APH1A*            High expression (event)   75 (49)    68 (49)
                     Low expression (event)    97 (43)    34 (17)
  *PSENEN*           High expression (event)   101 (57)   56 (40)
                     Low expression (event)    71 (35)    46 (26)
  *NCSTN*            High expression (event)   127 (74)   57 (38)
                     Low expression (event)    45 (18)    45 (28)
  *PSEN2*            High expression (event)   79 (39)    86 (59)
                     Low expression (event)    93 (53)    16 (7)
  *APH1B*            High expression (event)   37 (10)    69 (47)
                     Low expression (event)    135 (82)   33 (19)

PSEN, presenilin; APH1, anterior pharynx-defective 1; PSENEN, presenilin enhancer protein 2; NCSTN, nicastrin.

###### 

Univariate cox regression results of each gene in TCGA and GSE21501 cohorts.

  A, TCGA                                                                                                                     
  ----------------- -------------------------------------------------------- ------------------ ----------------------------- -------
  *PSEN1*           0.00291^[b](#tfn3-ol-0-0-10113){ref-type="table-fn"}^    2.0355             1.275                         3.25
  *APH1A*           0.025^[a](#tfn2-ol-0-0-10113){ref-type="table-fn"}^      1.598              1.061                         2.408
  *PSENEN*          0.26                                                     1.275              0.8353                        1.946
  *NCSTN*           0.0469^[a](#tfn2-ol-0-0-10113){ref-type="table-fn"}^     1.7011             1.007                         2.873
  *PSEN2*           0.0782                                                   1.4574             0.9583                        2.216
  *APH1B*           \<0.0001^[c](#tfn4-ol-0-0-10113){ref-type="table-fn"}^   3.2734             1.691                         6.335
                                                                                                                              
  **B, GSE21501**                                                                                                             
                                                                                                                              
  **Genes**         **P-value**                                              **Hazard ratio**   **95% confidence interval**   
                                                                                                                              
  *PSEN1*           0.0835                                                   1.5772             0.9414                        2.642
  *APH1A*           \<0.0001^[c](#tfn4-ol-0-0-10113){ref-type="table-fn"}^   2.724              1.517                         4.892
  *PSENEN*          0.0248^[a](#tfn2-ol-0-0-10113){ref-type="table-fn"}^     1.7894             1.076                         2.975
  *NCSTN*           0.371                                                    1.257              0.7623                        2.071
  *PSEN2*           0.195                                                    1.747              0.7517                        4.06
  *APH1B*           0.153                                                    1.4939             0.861                         2.592

P\<0.05

P\<0.01

P\<0.0001. PSEN, presenilin; APH1, anterior pharynx-defective 1; PSENEN, presenilin enhancer protein 2; NCSTN, nicastrin; TCGA, The Cancer Genome Atlas.

###### 

Differences in gene expression between cancerous and normal tissues.

             GSE28735   GSE15471   GSE16515                                                 
  ---------- ---------- ---------- ---------- --------- ------- ------- --------- --------- ---------
  *PSEN1*    \<0.001    6.462      5.932      \<0.001   5.677   5.503   \<0.001   85.603    50.961
  *APH1A*    \<0.001    5.799      5.476      0.002     6.416   6.282   \<0.001   211.812   144.006
  *PSENEN*   \<0.001    6.347      6.038      0.006     7.726   7.456   \<0.001   168.60    107.950
  *NCSTN*    0.016      6.162      6.024      \<0.001   6.635   6.732   0.0501    154.240   134.207
  *PSEN2*    \<0.001    5.251      5.689      \<0.001   6.045   6.625   0.032     38.227    58.335
  *APH1B*    0.41       5.123      5.035      \<0.001   6.952   6.688   0.504     57.535    60.265

PSEN, presenilin; APH1, anterior pharynx-defective 1; PSENEN, presenilin enhancer protein 2; NCSTN, nicastrin.
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